Novel A2AAR antagonists for cancer immunotherapy continue to be synthesized and developed [184,185], including dual-acting compounds targeting both A2AARs and other well-recognized cancer targets such as histone deacetylases [186,187] or CD73 [188]. Here, NT5E is linked to cancer.